Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors

Hepato-Gastroenterology

Volumn 52, Issue 63, 2005, Pages 826-828

  Lai, I Rue ^a   Hu, Rey Heng ^a   Chang, King Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Gastrointestinal stromal tumor; Imatinib

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ANAMNESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; CLINICAL EXAMINATION; DRUG INDICATION; EDEMA; FACE EDEMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; METASTASIS; NAUSEA; NEUTROPENIA; ORBIT DISEASE; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GASTROINTESTINAL STROMAL TUMORS; HUMANS; ILEAL NEOPLASMS; JEJUNAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 20644433357     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Plaat BE, Hollema H, Molenaar WM, et al: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin One 2000; 18:3211-3220.
2. Lasota J, Jasinski M, Sarlomo-Rikala M, et al: Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal tumors and do not occur in leiomyoma or leiomyosarcomas. Am J Pathol 1999; 154:53-60.
3. Miettinen M, Sarlomo-Rikala M, Lasota J: Gastrointestinal stromal tumors: recent advanced in understanding of their biology. Hum Pathol 1999; 30:1213-1220.
4. Hirota S, Isozaki K, Moriyama Y, et al: Gain of function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
5. Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid leukemia. Blood 2000; 96:3343-3356.
6. Goldman JM: Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet 2000; 355:1031-1032.
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al: Effect of tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
8. Blanke CD, von Mehren M, Joensuu H, et al: Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD117). Prog Proc Am Soc Clin Oncol 2001; 20:1a. (Abstract)
9. van Oosterom AT, Judson I, Verweij J, et al: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358:1421-1423.
10. Lasota J, Jasinski M, Sarlomo-Rikala M et al: Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal tumors and do not occur in leiomyoma or leiomyosarcomas. Am J Pathol 1999; 154:53-60.
11. Strickland L, Letson GD, Muro-Cacho CA: Gastrointestinal stromal tumors. Cancer Control. 2001; 8:252-261.
12. Emory TS, Sobin LH, Lukes L, et al: Prognosis of gastrointestinal smooth -muscle (stromal) tumors: dependence on anatomic site. Am J Pathol 1999; 23:82-87.
13. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231(1):51-58.
14. Sawyers CL: Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Semin Hematol 2001; 38(Suppl 8):15-21.
15. Druker BJ, Sawyers CL, Kantarjian, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1052-1056.